PDF下载 ( 284 KB)
Expert consensus on antiviral therapy for specific patients with chronic hepatitis B
-
-
[1]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识:2009年更新[DB].中华实验和临床感染病杂志:电子版, 2009, 3 (1) :69-79. [2]Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531. [3]Schiff E, Lai CL, Hadziyannis S, et al.Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-re-sistant hepatitis B:final long-term results[J].Liver Transpl, 2007, 13 (3) :349-360. [4]Schiff E, Lai CL, Neuhaus P, et al.Adefovir dipivoxil for the treat-ment of chronic hepatitis B in patients pre and post liver transplanta-tion with lamivudine resistant hepatitis B virus patients[J].Hepatol-ogy, 2003, 38 (6) :1419-1427. [5]Lange CM, Bojunga J, Hofmann WP, et al.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function[J].Hepatology, 2009, 50 (6) :2001-2006. [6]Roussos A, Koilakou S, Kalafatas I, et al.Lamivudine treatment for acute severe hepatitis B:report of a case and review of the literature[J].Acta Gastroenterol Belg, 2008, 71 (1) :30-32. [7]Tillmann HL, HademJ, Leifeld L, et al.Safety and efficacy of lami-vudine in patients with severe acute or fulminant hepatitis B, a multi-center experience[J].J Viral Hepat, 2006, 13 (4) :256-263. [8]王融冰, 周桂琴, 江宇泳, 等.799例重型肝炎患者的临床病原学与实验室分析[J].中华肝脏病杂志, 2006, 14 (9) :655-657. [9]Wong VW, Wong GL, Tsang SW, et al.Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg) -positive chronic hepatitis B[J].Antivir Ther, 2008, 13 (4) :571-579. [10]Seehofer D, Rayes N, Naumann U, et al.Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive pa-tients undergoing liver transplantation[J].Transplantation, 2001, 72 (8) :1381-1385. [11]Terrault N, Roche B, Samuel D.Management of the hepatitis B vi-rus in the liver transplantation setting:a European and an American perspective[J].Liver Transpl, 2005, 11 (7) :716-732. [12]Roque-Afonso AM, Feray C, Samuel D, et al.Antibodies to hep-atitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors[J].Gut, 2002, 50 (1) :95-99. [13]Breitenstein S, Dimitroulis D, Petrowsky H, et al.Systematic re-viewand meta-analysis of interferon after curative treatment of hepa-tocellular carcinoma in patients with viral hepatitis[J].Br J Surg, 2009, 96 (9) :975-981. [14]Nagamatsu H, Itano S, Nagaoka S, et al.Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepat-ic arterial infusion chemotherapy[J].Am J Gastroenterol, 2004, 99 (12) :2369-2375. [15]Kuzuya T, Katano Y, Kumada T, et al.Efficacy of antiviral thera-py with lamivudine after initial treatment for hepatitis B virus-relat-ed hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2007, 22 (11) :1929-1935. [16]Nagano H, Monden M.FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma[J].Nippon Rinsho, 2006, 64 (7) :1314-1318. [17]Lok AS, McMahon BJ.Chronic hepatitis B:update2009[J].Hepatology, 2009, 50 (3) :661-662. [18]Jonas MM, Mizerski J, Badia IB, et al.Clinical trial of lamivudinein children with chronic hepatitis B[J].N Engl J Med, 2002, 346 (22) :1706-1713. [19]Tran TT.Management of hepatitis B in pregnancy:weighing the op-tions[J].Cleve Clin J Med, 2009, 76 (Suppl3) :S25-S29. [20]Xu WM, Cui YT, Wang L, et al.Efficacy and safety of lamivudine in late pregnancy for prevention of mother-child transmission of hep-atitis B:a multicenter, randomized, double blind, placebo-con-trolled study[J].Hepatology, 2004, 40 (Suppl1) :272A. [21]张丽菊, 王玲.替比夫定对妊娠后期乙型肝炎病毒宫内感染的阻断作用[J].中华肝脏病杂志, 2009, 17 (8) :561-563. [22] 慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识[DB].中华实验和临床感染病杂志, 电子版:2009, 3 (3) :343-352. [23]Sherman M.Strategies for managing coinfection with hepatitis B vi-rus and HIV[J].Cleve Clin J Med, 2009, 76 (Suppl3) :S30-33. [24]Chuang TW, Hung CH, Huang SC, et al.Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glo-merulopathy after lamivudine monotherapy[J].J Formos Med Assoc, 2007, 106 (10) :869-873. [25]Okuse C, Yotsuyanagi H, Yamada N, et al.Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudi-ne[J].Clin Nephrol, 2006, 65 (1) :53-56. [26]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B[J].N Engl J Med, 2005, 352 (26) :2673-2681. [27]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].N Engl J Med, 2003, 348 (9) :808-816. [28]Morgan M, Keeffe EB.Diagnosis and treatment of chronic hepatitis B:2009update[J].Minerva Gastroenterol Dietol, 2009, 55 (1) :5-22. [29]Kansu A, Kuloglu Z, Demirceken F, et al.Autoantibodies in chil-dren with chronic hepatitis B infection and the influence of interferon alpha[J].Turk J Gastroenterol, 2004, 15 (4) :213-218. [30]Deutsch M, Dourakis S, Manesis EK, et al.Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa thera-py[J].Hepatology, 1997, 26 (1) :206-210. [31]Loomba R, Rowley A, Wesley R, et al.Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med, 2008, 148 (7) :519-528. [32]Hui CK, Cheung WW, Au WY, et al.Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematologi-cal malignancy on completion of cytotoxic chemotherapy[J].Gut, 2005, 54 (11) :1597-1603. [33]European Association For The Study of The Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepa-tol, 2009, 50 (2) :227-242. -
本文二维码
计量
- 文章访问数: 3142
- HTML全文浏览量: 6
- PDF下载量: 1116
- 被引次数: 0
下载:
